Madrigal Pharmaceuticals (YDO1) AI Stock Analysis

Madrigal Pharmaceuticals

(XETRA:YDO1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Rapid Rezdiffra adoptionRezdiffra is demonstrating strong commercial traction, with rapid sales growth and a patient base that more than doubled year over year. Broad access, prescriber depth, adherence, and continued patient additions support a durable revenue expansion opportunity over the coming quarters.

Negative Factors

Persistent losses and cash burnDespite the revenue ramp, Madrigal has not yet converted commercialization into positive operating or free cash flow. Continued cash consumption can restrict funding flexibility and may require the company to rely on its available resources until sales growth sufficiently exceeds operating and development costs.

Madrigal Pharmaceuticals (YDO1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.94B
Dividend Yield: ―
Average Volume (3M): 9
Price to Earnings (P/E): -33.4
Beta (1Y): -0.24
Revenue Growth: 133.47%
EPS Growth: 6.82%
Country: Germany
Employees: 915
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Madrigal Pharmaceuticals Business Overview & Revenue Model

Company Description

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced...

Madrigal Pharmaceuticals Earnings Call Summary

Earnings Call Date:Jul 29, 2026(Q2-2026)|% Change Since:-19.31%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call was strongly positive, driven by 71% year-over-year net sales growth, a patient base that more than doubled, progress past 50,000 patients, expanding market opportunity, encouraging real-world and clinical data, strengthened intellectual property, and a rapidly advancing pipeline. The main negatives were higher operating costs, a wider net loss, lower cash compared with year-end, negligible near-term European contribution due to reimbursement challenges, and continued uncertainty around the precise timing and event-rate dynamics of the F4-C trial. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Rezdiffra Net Sales Growth

Second-quarter 2026 net sales were $364.3 million, representing 71% year-over-year growth. Management said demand remains strong and that the product is tracking in line with, and in many cases exceeding, best-in-class specialty launches.

Negative Updates

Higher Cost of Sales

Second-quarter 2026 cost of sales was $40.0 million, compared with $9.1 million in the prior-year period. The increase was primarily driven by higher royalties payable to Roche and a write-down of certain work-in-process inventory.

Company Guidance

Management expects Rezdiffra to continue to steadily add patients, with robust net sales growth for 2026, and is comfortable with the consensus quarterly growth rates for the rest of the year; growth to net discount is expected to be in the mid to high 30s for this year, the MASH market is expected to expand at a double-digit pace for the foreseeable future, full year 2026 R&D expenses are expected to be roughly the same as 2025, and full year 2026 SG&A expenses are expected to increase compared to 2025. The company expects to initiate 3 phase II trials in 2027, expects the F4-C MAESTRO Outcomes study to read out in 2027 and the F2-F3 MAESTRO-NASH study to provide data in 2028, and expects Europe’s contribution to be negligible for the year.

Madrigal Pharmaceuticals Risk Analysis

Madrigal Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Madrigal Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Madrigal Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:YDO1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	81Outperform	$16.93B	20.11	45.54%	―	9.12%	40.53%
ASND	68Neutral	$15.67B	18.53	190.44%	―	128.41%	―
ROIV	54Neutral	$26.66B	-97.13	-6.12%	―	-67.58%	45.61%
BBIO	53Neutral	$14.60B	-24.65	26.76%	―	167.27%	27.40%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IONS	48Neutral	$7.23B	-12.58	-110.84%	―	-7.49%	-98.12%

* Healthcare Sector Average

Performance Comparison

DE:YDO1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:YDO1	Madrigal	385.20	-0.50	-0.13%
EXEL	Exelixis	69.39	31.49	83.09%
IONS	Ionis Pharmaceuticals Inc.	43.52	-29.36	-40.29%
ASND	Ascendis Pharma A/S	251.27	43.03	20.66%
BBIO	Bridgebio Pharma	74.95	13.58	22.13%
ROIV	Roivant Sciences Ltd.	36.91	17.04	85.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Madrigal Pharmaceuticals AI Stock Analysis